Abcam, ab250756, Anti-Troponin I fast skeletal muscle antibody [EPR14927(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Troponin I fast skeletal muscle antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14927(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250756 is the carrier-free version of
ab184554
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Troponin I fast skeletal muscle also known as TNNI2 is a protein involved in muscle contraction. It weighs around 21.2 kDa and is mainly expressed in fast-twitch skeletal muscle. TNNI2 acts by inhibiting actomyosin ATPase activity meaning it helps prevent muscle contraction until it receives a signal to contract. It binds to actin and plays a regulatory role in the muscle contraction process.
Biological function summary
Troponin I fast skeletal muscle interacts within the troponin complex which includes Troponin T and Troponin C. Located on the thin filament of the muscle fiber this complex modulates the contraction of striated muscle by controlling calcium binding. When calcium binds to Troponin C it induces a conformational change that displaces TNNI2 from actin allowing for muscle contraction to occur.
Pathways
Troponin I fast skeletal muscle has essential functions in the calcium modulation pathways specific to muscle contraction. It plays an important role in the regulation of muscle contraction by interacting with calcium ions and other proteins such as tropomyosin. As part of the excitation-contraction coupling pathway TNNI2 helps ensure the proper contraction of muscles in response to neural stimulation. Additionally its role in these pathways involves specific interactions with proteins like Troponin C and Troponin T which are necessary for functional muscle contraction.
Abnormalities in Troponin I fast skeletal muscle can lead to muscle-related conditions such as nemaline myopathy and distal arthrogryposis. These disorders affect muscle structure and function leading to muscle weakness or deformities. Mutations in TNNI2 may result in improper interaction with other sarcomeric proteins such as tropomyosin disrupting normal muscle contraction and leading to the mentioned diseases. Understanding the role of TNNI2 in these disorders can aid in the development of diagnostic and therapeutic strategies.